Company History

2019

– Medicilon Inc. – Announcement of an IPO on Sci-Tech Innovation Board in China
– (stock code : 688202.SH)
– Fifteenth Anniversary Celebration Series
– Passed the Review of GLP & AAALAC

2018

– Nanhui R&D Center Officially Operate
– IND approved in Sweden

2017

– Medicilon established the preclinical cardiac safety assessment study platform
– Established the clinical BE biological analysis platform
– Established an inhalation and ophthalmic administration evaluation platform
– Established the registration and declaration service platform
– Expand the Tumor Center
– The introduction of new high-throughput Biacore experimental instrument
– The introduction of new multiple LC-MS / MS mass spectrometers

2016

– Medicilon was awarded as “Shanghai Academicians and Experts Workstation Qualified Unit”
– Medicilon completed the construction of preparation center and microbial laboratory
– Medicilon completed the construction of preparation center and GMP pilot plant
– Established the tumor immunology service platform
– Established the biotechnology drug and bioanalysis service platform
– Established the ADC (Antibody Drug Conjugate) preclinical service platform
– Establish a “Generic Drug Quality Consistency Assessment Service Platform”
– The introduction of the new mass spectrometer, Triple Quad 6500
– The introduction of the new IVIS Lumina III Imaging System

2015

– Expansion of the New Laboratory Area with 10,000 square meters
– Medicilon held first Congress of Science and Technology Association

2014

– Tenth Anniversary Celebration Series

– Approved the Establishment of Academicians and Experts Workstations

– Expansion of the New Laboratory Area with 10,000 square meters

– Expand Isotope Biomarker Services

– Passed the Review of CFDA GLP

2013

Successfully introduce new foreign drugs to domestic pharmaceutical companies

Establishment of new three party collaboration model: Foreign Enterprise – Medicilon – Domestic Pharmaceutical Company

Chinese government officially approve Shanghai Medicilon Inc. become the holding company of MPI Preclinical Research (Shanghai) LLC.

2012

– Participate the filming of “DaDaoTongXing” as the representative of Shanghai high-tech enterprises
– Provide the complete application for both CFDA and US FDA IND filing
– Three party collaboration to promote the drug development process
– Undertake the “Twelve Five Year Project” on creating new drug task
– GLP is successfully reviewed by both US FDA and CFDA

2011

– China’s SFDA officially approved Medicilon’s GLP Certification
– Medicilon recognized as a “Cultivated Little Giant Enterprise” in Shanghai’s High Technology Industry

2010

– Fortune Capital signed investment agreement with Medicilon aimed for IPO in China
– Medicilon is recognized as one of the top seven integrated services CRO in China in Citi Investment’s report
– Medicilon’s “Shanghai Isotope Drug Metabolism Professional and Technical Services Platform”, was selected as the first batch of “Shanghai Professional and Technical Service Platform”

2009

– Medicilon acquires international AAALAC Accreditation
– Medicilon preclinical research facilities compliance with US GLP standard
– “Protein-crystallography-based Drug Discovery and Screen Platform” of Medicilon was listed in Shanghai R&D Public
– “NHP Experimental Service Platform” of Medicilon/MPI was listed in Shanghai R&D Public Service Platforms
– Medicilon established CMC platform

2008

– Animal facility in Medicilon approved by Shanghai Animal Committee, was issued the License of Laboratory Animal (Rat, Mouse, Dog and Monkey).
– The joint venture company, Medicilon Preclinical Research, registered in Shanghai, begins to provide preclinical GLP services
– Laboratories expanded to 20,000 square meters in the Chuansha campus which include the largest animal facility (40 animal rooms) in Shanghai

2007

– Joint Venture agreement between Shanghai Medicilon Inc. and MPI Research signed
– Commenced non-GLP preclinical research and projects

2006

– Medicilon was acknowledged as Hi-tech Enterprise by Shanghai Science Commission

2005

– Trademark “美迪西” (Medicilon Inc.) approved by Chinese government
– Animal facilities were issued their respective licenses (Rat, Mouse, Rabbit, Dog and Non-human primates)
– Established the first chemical synthesis FTE team

2004

– Medicilon registered in Shanghai, Laboratory construction in Zhangjiang Hi-tech Park
– Initially provided Chemistry and Bioanalysis Services
– First LC/MC/MC was imported for pharmacokinetics services